Increased elective procedure volume recovery lifts market growth to new heights

The winds of change precipitated a strong season of growth for the Total Joints Market. Company after company reported increasing elective procedural volume recovery due to the underlying post-COVID demand. Procedure momentum and easier year-over-year comparisons drove market growth above double-digits with the US Total Joints Market growing +14.5% in Q123. Easing of staffing headwinds and normalization of surgery cancellation rates were also contributing factors to accelerating procedures.

 

Strong growth across market segments and new products coming to market signal continuing Extremities Market strength

SmartTRAK reports that the Q422 WW Extremities Market, WW Upper Extremities Market, WW Foot & Ankle Market, US Extremities Market, US Upper Extremities Market and the US Foot & Ankle Market were all up between +4.5% and +9.0% YoY.

 

AAOS approaches “Next to Normal” as surgeons and industry focus on solutions to meet the needs of patients returning to joint replacement

If an ad agency had branded the American Academy of Orthopedic Surgeons (AAOS) 2023 Annual Meeting this year, the tagline would have read “Getting back to normal.” Surgeons toured the exhibit hall throughout the day not just during dedicated hours. The meeting felt as if it had come back to life with industry symposiums and conference presentations often seeing standing-room-only crowds when a few years ago even the exhibit floor felt like a ghost town. And while some of the large orthopedic companies slightly scaled down their booth space, several mid-tier and small market players increased their presence at the meeting in an attempt to pique surgeon interest. So what was the buzz at AAOS 2023 related to hip and knee replacement? In this article, SmartTRAK outlines some of the key takeaways, including: 

• Procedure Recovery May Signal Return of Deferred Procedures
  • Both clinicians and company representatives at the meeting revealed to SmartTRAK that they are seeing increased hip and knee procedure volumes heading into 2023. The overall consensus was ...
    
    
• The Move to Outpatient Joint Replacement Continues.
  • Data presented at AAOS 2023 continues to support the move of joint replacement surgeries to an outpatient setting. A study focusing on patient satisfaction after outpatient joint replacement in an academic medical center reported ...
    
    
• Cementless Knee Trend Growing Despite Mixed Results
  • Clinical evidence presented at AAOS showed mixed results for cementless total knees with some studies reporting excellent outcomes and others identifying increased risks associated with ...
    
    
• Assistive Technologies Growing and Evolving
  • Assistive technology presentations and booth exhibits seemed to generate the most interest at AAOS 2023. Elise Wolf, SmartTRAK’s assistive technologies expert, noted the most innovative products and ...
    
    

To download and read the complete "AAOS 2023: Total Joint Viewpoint" article by SmartTRAK's Lisa Mahan,  VP Product Development & IT, Sr. Analyst TJ&E, just click the button below.

Procedure recovery above Q4 seasonality, new products and assistive tech push strong revenue growth

  For Q422, the US Hip Replacement Market grew +8.4% according to SmartTRAK Financial Dashboard . Newer products, implant pull-through from assistive technologies and procedure recovery continued to positively impact growth. Nearly all companies in our reporting universe cited procedure recovery as a growth driver.

 

The US Knee Replacement Market grew +9.3% in Q422, driven in part by knee procedure recovery. Recovery appeared to be above that of the typical year-end seasonality of patients trying to fit in surgery before insurance deductibles reset. SmartTRAK has heard rumblings that the growth seen in Q4 may be a sign that ...

 

To read more about the strong revenue growth in the Total Joints Market, including Procedure Recovery, New Products and Assistive Technologies Driving Growth in the Hip Market and Cementless Knees and Enabling Tech Expanding the Knee Market, just click the link below.

Read the entire Q422 Total Joints Market Recap, including SmartTRAK's expert analysis, news, data, charts, company revenues and shares*  

 

* This link and the complete unedited article can only be viewed by SmartTRAK  subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please  click  the button below.

SmartTRAK examines conditions lowering the flame for Total Joints

 

An analyst from JP Morgan has  drawn  parallels between the current behavior of the US stock and bond markets and the conditions leading up to the 1969 recession, according to a recent  Forbes  article. Interest rate hikes and high inflation have increased the likelihood that the US economy will face a recession in 2023. But what does that mean for the Total Joints Market?

 

SmartTRAK highlights trends affecting the US Extremities Market in 2023

The Extremities Market continues to be a hotbed of activity heading into 2023. SmartTRAK highlights trends that will continue to affect the US Market for Extremities in 2023, including CMS reimbursement obstacles, new product introductions and potential mergers and acquisitions.

 

Among the many topics covered in detail in this comprehensive article are:

• SmartTRAK's Expert Market Analysis and Insights
• Outpatient Shoulder Replacement Growing Despite Lack of CMS Reimbursement
• New Shoulders May Heat Up Competition
• New Ankle Products and Technologies May Boost Growth
• New Products, DTC and Potential M&As Heat Up Extremities Fixation
• M&As on the Horizon

To download and read the complete "2023 Extremities Trends to Watch" article, just click the button below.

The countdown to AAOS 2023 on March 7-11 in Las Vegas has begun and the SmartTRAK team will be attending...see you there!

Highlighting the economic conversation at AAHKS 2022 changing the landscape of joint replacement

At the American Association of Hip and Knee Surgeons (AAHKS) 2022 Annual Meeting in Dallas, SmartTRAK identified economics as a leading conversation theme under the guise of other topics. AAHKS 2022 itself was not immune to rising economic pressures as many clinicians were rumored to have backed out of attending the meeting and several exhibiting companies scaled down their participation as well. Surgeons not only attended sessions to enhance their clinical knowledge, but they also discussed facing the challenges of reduced reimbursement. In the exhibit hall, Companies featured products and technologies seemingly geared towards the shift of hip and knee replacement procedures to the more cost-conscious ambulatory surgery center (ASC) setting.

Among the many topics covered in detail in the complete article, which can be downloaded here, are:

• Economic Pressures
• Reimbursement Challenges 
• The Decline of CMS Physician Primary Hip Replacement Reimbursement
• Manufacturers Targeting ASCs, including:
  
  • Smith& Nephew
  • ConFormMIS
  • Exactech
  • Maxx Medical
  • DePuy Synthes

Hip Innovation Technology is betting on its Reverse HRS Hip to change the practice of total hip replacement

Most recent innovations in hip replacement have focused on the use of new materials, new surgical approaches and new assistive technologies. However, one company, Hip Innovation Technology* (HIT), is betting on its investment to change the practice of total hip replacement with an innovative design resulting in the world’s first reverse hip system. The Company is getting even closer to realizing a payoff on this bet by receiving US FDA Investigational Device Exemption (IDE) approval in January 2022 to initiate a pivotal multi-center clinical trial to evaluate the HIT Reverse Hip Replacement System (Reverse HRS)*. Most likely, HIT will be ready to submit for FDA approval of the device following the primary completion of the IDE trial slated for July 2026.

Who is Hip Innovation Technology?

Located in Boca Raton, Florida, Hip Innovation Technology is a privately held company formed in 2011 with the vision of developing and marketing orthopedic device solutions. The Company got its start through a seed round of funding with an initial raise of $225K. George Diamantoni, chief executive officer, is also the founder and CEO of Joint Innovation Technology, HIT’s parent company. He has over 25 years of experience in the healthcare industry including positions at The Upjohn Company, Pharmacia Corporation, Pfize, and Schering Plough. Zafer Termanini, MD, FACS, the inventor of the Interlocking Reverse Hip, serves as the president and chief medical officer of HIT. Termanini, an orthopedic surgeon with over 30 years of experience, is also a Diplomate of the American College of Disability Analysts and the American College of Forensic Examiners, with specialties in Orthopedic and Joint Reconstruction, Sports Medicine and Biomechanical Analysis.

What is a Reverse Hip Replacement?